Filtered By:
Specialty: Cancer & Oncology
Condition: Heart Failure
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 141 results found since Jan 2013.
Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research
Association Between Aromatase Inhibitors and Myocardial Infarction Morbidity in Women With Breast Cancer: A Meta-Analysis of Observational Studies
CONCLUSION: Based on real-world data, AIs may be a safe treatment route for patients with estrogen receptor-positive breast cancer and those with a history of CVD. AIs caused a major decrease in MI in patients without CVD history. However, more in-depth investigations are needed to explore the association between AI use and the incidence of MI in the treatment of estrogen receptor-positive breast cancer.PMID:36346929 | DOI:10.1177/10732748221132512
Source: Cancer Control - November 8, 2022 Category: Cancer & Oncology Authors: Jing-Chao Sun Ze-Fan Sun Chao-Jie He Chang-Lin Zhai Gang Qian Source Type: research
Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study
CONCLUSIONS: Exposure to adjuvant fluoropyrimidine-based chemotherapy was associated with an increased risk of CVD among survivors of high-risk stage II-III CRC. Cardiovascular risk monitoring of this group throughout cancer survivorship is advisable.PMID:36240841 | DOI:10.6004/jnccn.2022.7042
Source: Journal of the National Comprehensive Cancer Network : JNCCN - October 14, 2022 Category: Cancer & Oncology Authors: Shing Fung Lee Pui Lam Yip Balamurugan A Vellayappan Cheng Ean Chee Lea Choung Wong Eric Yuk-Fai Wan Esther Wai-Yin Chan Chak-Fei Lee Francis Ann-Shing Lee Miguel Angel Luque-Fernandez Source Type: research
Risk of mortality and other adverse outcomes from myocardial infarction in cancer survivors: a meta-analysis
ConclusionThis meta-analysis shows that cancer increases the risk of all-cause mortality, recurrent MI, and major bleeding in MI patients but is not associated with the risk of cardiovascular death. Therefore, comprehensive multidisciplinary management and monitoring of potential future adverse events in MI patients with cancer are needed.Systematic review registrationThe meta-analysis was registered in the International Register of Prospective Systematic Reviews (NO. CRD42022332775).
Source: International Journal of Clinical Oncology - November 28, 2022 Category: Cancer & Oncology Source Type: research
A view of care pathways approved by Italian Regions, to face the challenge of the community-based healthcare: a quali-quantitative analysis of the Pdta Net database.
CONCLUSIONS: The high number of CPs approved in Italy confirms an increasing interest of the healthcare institutions. The collected CPs show an extreme variety of titles, text structures and disease choices. Given the absence of an institutional observatory and of devotees of shared and harmonized CPs, annually Pdta Net makes available an updated and complete overview of these governance tools, which are essential for the upcoming changes of the Italian national health service.PMID:36573531 | DOI:10.1701/3939.39228
Source: Cancer Control - December 27, 2022 Category: Cancer & Oncology Authors: Irene Dell'Anno Silvia Calabria Letizia Dondi Giulia Ronconi Leonardo Dondi Alice Addesi Antonella Pedrini Immacolata Esposito Aldo Pietro Maggioni Nello Martini Carlo Piccinni Source Type: research
Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - December 31, 2022 Category: Cancer & Oncology Source Type: research
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk
CONCLUSIONS: Compared with GnRH agonists, the GnRH antagonist was found to be associated with a decreased risk of HF, specifically among patients with prior CVD. Among those with no prior CVD, the GnRH antagonist was associated with a decreased risk of IHD but an increased risk of arrhythmia.PMID:36791755 | DOI:10.6004/jnccn.2022.7083
Source: Journal of the National Comprehensive Cancer Network : JNCCN - February 15, 2023 Category: Cancer & Oncology Authors: Alice Dragomir Nawar Touma Jason Hu Sylvie Perreault Armen G Aprikian Source Type: research
